OBJECTIVES: This study sought to determine whether the extent of late gadolinium enhancement (LGE) can provide additive prognostic information in patients with a nonischemic dilated cardiomyopathy (NIDC) with an indication for implantable cardioverter-defibrillator (ICD) therapy for the primary prevention of sudden cardiac death (SCD). BACKGROUND: Data suggest that the presence of LGE is a strong discriminator of events in patients with NIDC. Limited data exist on the role of LGE quantification. METHODS: The extent of LGE and clinical follow-up were assessed in 162 patients with NIDC prior to ICD insertion for primary prevention of SCD. LGE extent was quantified using both the standard deviation-based (2-SD) method and the full-width half-maximum (FWHM) method. RESULTS: We studied 162 patients with NIDC (65% male; mean age: 55 years; left ventricular ejection fraction [LVEF]: 26 ± 8%) and followed up for major adverse cardiac events (MACE), including cardiovascular death and appropriate ICD therapy, for a mean of 29 ± 18 months. Annual MACE rates were substantially higher in patients with LGE (24%) than in those without LGE (2%). By univariate association, the presence and the extent of LGE demonstrated the strongest associations with MACE (LGE presence, hazard ratio [HR]: 14.5 [95% confidence interval (CI): 6.1 to 32.6; p < 0.001]; LGE extent, HR: 1.15 per 1% increase in volume of LGE [95% CI: 1.12 to 1.18; p < 0.0001]). Multivariate analyses showed that LGE extent was the strongest predictor in the best overall model for MACE, and a 7-fold hazard was observed per 10% LGE extent after adjustments for patient age, sex, and LVEF (adjusted HR: 7.61; p < 0.0001). LGE quantitation by 2-SD and FWHM both demonstrated robust prognostic association, with the highest MACE rate observed in patients with LGE involving >6.1% of LV myocardium. CONCLUSIONS: LGE extent may provide further risk stratification in patients with NIDC with a current indication for ICD implantation for the primary prevention of SCD. Strategic guidance on ICD therapy by cardiac magnetic resonance in patients with NIDC warrants further study.
OBJECTIVES: This study sought to determine whether the extent of late gadolinium enhancement (LGE) can provide additive prognostic information in patients with a nonischemic dilated cardiomyopathy (NIDC) with an indication for implantable cardioverter-defibrillator (ICD) therapy for the primary prevention of sudden cardiac death (SCD). BACKGROUND: Data suggest that the presence of LGE is a strong discriminator of events in patients with NIDC. Limited data exist on the role of LGE quantification. METHODS: The extent of LGE and clinical follow-up were assessed in 162 patients with NIDC prior to ICD insertion for primary prevention of SCD. LGE extent was quantified using both the standard deviation-based (2-SD) method and the full-width half-maximum (FWHM) method. RESULTS: We studied 162 patients with NIDC (65% male; mean age: 55 years; left ventricular ejection fraction [LVEF]: 26 ± 8%) and followed up for major adverse cardiac events (MACE), including cardiovascular death and appropriate ICD therapy, for a mean of 29 ± 18 months. Annual MACE rates were substantially higher in patients with LGE (24%) than in those without LGE (2%). By univariate association, the presence and the extent of LGE demonstrated the strongest associations with MACE (LGE presence, hazard ratio [HR]: 14.5 [95% confidence interval (CI): 6.1 to 32.6; p < 0.001]; LGE extent, HR: 1.15 per 1% increase in volume of LGE [95% CI: 1.12 to 1.18; p < 0.0001]). Multivariate analyses showed that LGE extent was the strongest predictor in the best overall model for MACE, and a 7-fold hazard was observed per 10% LGE extent after adjustments for patient age, sex, and LVEF (adjusted HR: 7.61; p < 0.0001). LGE quantitation by 2-SD and FWHM both demonstrated robust prognostic association, with the highest MACE rate observed in patients with LGE involving >6.1% of LV myocardium. CONCLUSIONS: LGE extent may provide further risk stratification in patients with NIDC with a current indication for ICD implantation for the primary prevention of SCD. Strategic guidance on ICD therapy by cardiac magnetic resonance in patients with NIDC warrants further study.
Authors: R J Kim; D S Fieno; T B Parrish; K Harris; E L Chen; O Simonetti; J Bundy; J P Finn; F J Klocke; R M Judd Journal: Circulation Date: 1999-11-09 Impact factor: 29.690
Authors: Leah Iles; Heinz Pfluger; Lisa Lefkovits; Michelle J Butler; Peter M Kistler; David M Kaye; Andrew J Taylor Journal: J Am Coll Cardiol Date: 2011-02-15 Impact factor: 24.094
Authors: Bojan Vrtovec; Reynolds Delgado; Aly Zewail; Cynthia D Thomas; Barbara M Richartz; Branislav Radovancevic Journal: Circulation Date: 2003-03-24 Impact factor: 29.690
Authors: Luciano C Amado; Bernhard L Gerber; Sandeep N Gupta; Dan W Rettmann; Gilberto Szarf; Robert Schock; Khurram Nasir; Dara L Kraitchman; João A C Lima Journal: J Am Coll Cardiol Date: 2004-12-21 Impact factor: 24.094
Authors: Jorge A Salerno-Uriarte; Gaetano M De Ferrari; Catherine Klersy; Roberto F E Pedretti; Massimo Tritto; Luciano Sallusti; Luigi Libero; Giacinto Pettinati; Giulio Molon; Antonio Curnis; Eraldo Occhetta; Fabrizio Morandi; Paolo Ferrero; Francesco Accardi Journal: J Am Coll Cardiol Date: 2007-10-22 Impact factor: 24.094
Authors: Frank M Bogun; Benoit Desjardins; Eric Good; Sanjaya Gupta; Thomas Crawford; Hakan Oral; Matthew Ebinger; Frank Pelosi; Aman Chugh; Krit Jongnarangsin; Fred Morady Journal: J Am Coll Cardiol Date: 2009-03-31 Impact factor: 24.094
Authors: Alan Kadish; Alan Dyer; James P Daubert; Rebecca Quigg; N A Mark Estes; Kelley P Anderson; Hugh Calkins; David Hoch; Jeffrey Goldberger; Alaa Shalaby; William E Sanders; Andi Schaechter; Joseph H Levine Journal: N Engl J Med Date: 2004-05-20 Impact factor: 91.245
Authors: P R Liebson; G Grandits; R Prineas; S Dianzumba; J M Flack; J A Cutler; R Grimm; J Stamler Journal: Circulation Date: 1993-02 Impact factor: 29.690
Authors: Rocio Hinojar; José Luis Zamorano; Ariana Gonzalez Gómez; Maria Plaza Martin; Amparo Esteban; Luis Miguel Rincón; Juan Carlos Portugal; José Julio Jimenez Nácher; Covadonga Fernández-Golfín Journal: Clin Cardiol Date: 2017-06-14 Impact factor: 2.882
Authors: Shiro Nakamori; An H Bui; Jihye Jang; Hossam A El-Rewaidy; Shingo Kato; Long H Ngo; Mark E Josephson; Warren J Manning; Reza Nezafat Journal: J Magn Reson Imaging Date: 2017-07-24 Impact factor: 4.813
Authors: Robert Jablonowski; Uzma Chaudhry; Jesper van der Pals; Henrik Engblom; Håkan Arheden; Einar Heiberg; Katherine C Wu; Rasmus Borgquist; Marcus Carlsson Journal: Circ Cardiovasc Imaging Date: 2017-09 Impact factor: 7.792
Authors: Sujith Kuruvilla; Nebiyu Adenaw; Arabindra B Katwal; Michael J Lipinski; Christopher M Kramer; Michael Salerno Journal: Circ Cardiovasc Imaging Date: 2013-12-20 Impact factor: 7.792